A phase I study of TAS-102 in combination with oxaliplatin (TAS-OX) for refractory metastatic colorectal cancer (mCRC).

被引：3

作者：

Cecchini, Michael

Kortmansky, Jeremy S.

Lacy, Jill

Fischbach, Neal A.

Thumar, Jaykumar Ranchodbhai

Sabbath, Kert D.

Gomez, Christina M.

Sporn, Jonathan

Stein, Stacey

Hochster, Howard S.

机构：

[1] Yale Univ, New Haven, CT USA

[2] Yale Sch Med, New Haven, CT USA

[3] Yale Univ, Smilow Canc Hosp, New Haven, CT USA

[4] Oncol Associates Bridgeport, Fairfield, CT USA

[5] St Francis Med Grp Inc, Middletown, CT USA

[6] Smilow Canc Hosp, Waterbury, CT USA

[7] Holy Cross Hosp, Biennes Canc Ctr, Ft Lauderdale, FL USA

[8] St Francis Hosp & Med Ctr, Hartford, CT USA

[9] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[10] SWOG, New Brunswick, NJ USA

来源：

关键词：

D O I：

10.1200/JCO.2019.37.4_suppl.630

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

630

引用

页数：2